[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Bidoli P, Bajetta E, Stani SC, De CD, Santoro A, Valente M, Zucali R, Valagussa P, Ravasi G, Bonadonna G: Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus. Cancer; 2002 Jan 15;94(2):352-61
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus.
  • BACKGROUND: The effects of multimodality treatment on the survival of patients with esophageal carcinoma are unclear.
  • The authors performed a prospective, Phase II study to assess the long-term results of chemotherapy plus radiotherapy (RT) on patients with esophageal squamous cell carcinoma.
  • Cisplatin (100 mg/m2 per day) on Day 1 and fluorouracil (1000 mg/m2 per day) on Days 1-4 were given for two cycles, with concomitant RT (30 grays [Gy] in 15 fractions) over 19 days.
  • Patients with potentially resectable tumors were then assessed for curative surgery; the other patients received two more courses of chemotherapy and further RT (20 Gy in 10 fractions).
  • RESULTS: Of 40 patients who were candidates for surgery, 32 patients underwent surgery, and 24 patients had complete resection; 8 patients (25%) had no residual tumor in the specimen, and 12 patients (37%) had microscopic foci only.
  • The larynx was preserved in 28% of 32 patients with cervical disease sites, with a 10-year disease free survival rate of 31%.
  • Three deaths were attributed to nonsurgical treatments.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiotherapy. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11900221.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. DiMusto PD, Orringer MB: Transhiatal esophagectomy for distal and cardia cancers: implications of a positive gastric margin. Ann Thorac Surg; 2007 Jun;83(6):1993-8; discussion 1998-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transhiatal esophagectomy for distal and cardia cancers: implications of a positive gastric margin.
  • BACKGROUND: A common operation for cancer of the esophagus and cardia consists of transhiatal esophagectomy, proximal gastrectomy, and a cervical esophagogastric anastomosis.
  • The oncologic adequacy of dividing the stomach 4 to 6 cm distal to palpable tumor is not well documented, and when a positive gastric margin is present on the final pathologic analysis, the appropriate management is not established.
  • This study was undertaken to determine the incidence of a positive gastric margin in these patients and the impact of adjuvant treatment.
  • METHODS: A retrospective review was performed of 1044 patients undergoing transhiatal esophagectomy for adenocarcinoma of the distal esophagus or cardia.
  • RESULTS: Nine patients (45%) received adjuvant therapy consisting of radiation in 3, chemotherapy in 4, or both in 2.
  • Their average postoperative survival was 477 days, compared with 455 days in those not receiving adjuvant therapy (p = 0.898).
  • Local tumor recurrence developed in 1 patient (11%) in the treatment group and in 3 (27%) in the no treatment group (p = 0.386).
  • CONCLUSIONS: A transhiatal esophagectomy and proximal gastrectomy for carcinoma of the distal esophagus and cardia, dividing the stomach 4 to 6 cm from palpable tumor, provides a negative gastric margin in 98% of patients.
  • In the few patients who have a positive gastric margin, 80% die with distant metastases, which would not be influenced by more extensive gastric resection, and in about 20%, local tumor recurrence develops in the intrathoracic stomach, seldom causing dysphagia.
  • Adjuvant therapy for a positive gastric margin neither improves survival nor reduces local tumor recurrence.
  • [MeSH-minor] Anastomosis, Surgical. Cardia / surgery. Combined Modality Therapy. Deglutition Disorders / prevention & control. Esophagus / surgery. Gastrectomy / methods. Humans. Neoplasm Recurrence, Local / prevention & control. Retrospective Studies. Stomach / surgery. Survival Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17532385.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


3. Zhang ZM, Xu ZG, Tang PZ, Xue LY, Lü N: [A retrospective analysis of anaplastic thyroid carcinoma]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun;28(3):322-4
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The clinical data of 58 patients (35 men, 23 women, aged 28 to 79 years) with ATC that were treated with various therapeutic modalities from 1981 to 2005 were retrospectively analyzed.
  • The dosage of postoperative radiotherapy was 40-70 Gy.
  • Only 2 patients received complete chemotherapy.
  • RESULTS: ATC invaded trachea in 40 patients (69.0%), esophagus in 32 patients (55.2%), and carotid in 17 patients (29.3%).
  • The cervical lymph node metastases occurred in 19 patients (32.8%).
  • In postoperative radiation < 60 Gy subgroup , the 5-year survival rate was 19.3%; however, in > or = 60 Gy group, it was 53.7% (P = 0.0000).
  • Among all the 58 patients, some patients received palliative surgery because of tumor invasion in trachea (n = 16, 27.6%), esophagus (n = 8, 13.8%), carotid (n = 8, 13.8%), and other sites (n = 13, 22.4%).
  • Twenty-four patients (61.5%) died of localrelapse, 2 (5.1%) of cervical lymphnode failure, 9 (23.1%) of metastasis, and 4 (10.3%) of other reasons.
  • Radical surgery and postoperative radiation > or = 60 Gy can improve the survival rate.
  • Tumor invasion in trachea, esophagus, and carotid are the main reasons of palliative surgery.
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16900624.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Markogiannakis H, Theodorou D, Toutouzas KG, Larentzakis A, Pattas M, Bousiotou A, Papacostas P, Filis K, Katsaragakis S: Small cell carcinoma arising in Barrett's esophagus: a case report and review of the literature. J Med Case Rep; 2008;2:15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma arising in Barrett's esophagus: a case report and review of the literature.
  • INTRODUCTION: Gastrointestinal tract small cell carcinoma is an infrequent and aggressive neoplasm that represents 0.1-1% of gastrointestinal malignancies.
  • Very few cases of small cell esophageal carcinoma arising in Barrett's esophagus have been reported in the literature.
  • An extremely rare case of primary small cell carcinoma of the distal third of the esophagus arising from dysplastic Barrett's esophagus is herein presented.
  • Esophagogastroscopy revealed an ulceroproliferative, intraluminar mass in the distal esophagus obstructing the esophageal lumen.
  • Contrast-enhanced chest and abdominal computed tomography demonstrated a large tumor of the distal third of the esophagus without any lymphadenopathy or distant metastasis.
  • Preoperative chemotherapy with cisplatine and etoposide for 3 months resulted in a significant reduction of the tumor.
  • After en block esophagectomy with two field lymph node dissection, proximal gastrectomy, and cervical esophagogastric anastomosis, the patient was discharged on the 14th postoperative day.
  • Histopathology revealed a primary small cell carcinoma of the distal third of the esophagus arising from dysplastic Barrett's esophagus.
  • The patient received another 3 month course of postoperative chemotherapy with the same agents and remained free of disease at 12 month review.
  • CONCLUSION: Although small cell esophageal carcinoma is rare and its association with dysplastic Barrett's esophagus is extremely infrequent, the high carcinogenic risk of Barrett's epithelium should be kept in mind.
  • Prognosis is quite unfavorable; a better prognosis might be possible with early diagnosis and treatment strategies incorporating chemotherapy along with oncological radical surgery and/or radiotherapy as part of a multimodality approach.
  • Since treatment protocols are not well established due to the rarity of the neoplasm, multi-institutional studies are needed to obtain sufficiently large populations for investigation and optimization of therapy of the disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1999 Nov;123(11):1123 [10539923.001]
  • [Cites] Diagn Cytopathol. 2000 Sep;23(3):180-2 [10945905.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):1-5 [12507278.001]
  • [Cites] Chest. 1995 Jan;107(1):179-81 [7813272.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2003 Jun;51(6):259-62 [12831243.001]
  • [Cites] J Pathol Bacteriol. 1952 Oct;64(4):889-91 [13000600.001]
  • [Cites] Ann Thorac Surg. 2002 Dec;74(6):1924-7 [12643374.001]
  • (PMID = 18211708.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2263060
  •  go-up   go-down


5. Makino H, Tajiri T, Onda M, Sasajima K, Miyashita M, Nomura T, Maruyama H, Nagasawa S, Tsuchiya Y, Hagiwara N, Yamashita K, Takubo K: Effectiveness of preoperative chemotherapy using carboplatin (CBDCA) and surgery against an esophageal small cell carcinoma. Dis Esophagus; 2002;15(3):237-41
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of preoperative chemotherapy using carboplatin (CBDCA) and surgery against an esophageal small cell carcinoma.
  • Radiologic and endoscopic examination disclosed a 2.0-cm exophytic tumor in the middle third of the esophagus.
  • Computed tomography of the chest, abdomen, and cervical region was performed, as were gallium and bone scintigraphy.
  • After neoadjuvant chemotherapy with carboplatin (CBDCA) (400 mg/m2) and etoposide (VP-16) (100 mg/m2), endoscopy and barium-swallow esophagography showed regression.
  • Thoracic esophagectomy then was performed with mediastinal, abdominal and cervical lymph node dissection.
  • The resected tumor was polypoid, measuring 0.5 x 0.5 cm.
  • The patient has survived for more than 7 months with no further treatment and no evidence of recurrent disease.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12444997.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


6. Yamada K, Murakami M, Okamoto Y, Okuno Y, Nakajima T, Kusumi F, Takakuwa H, Matsusue S: Treatment results of radiotherapy for carcinoma of the cervical esophagus. Acta Oncol; 2006;45(8):1120-5
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of radiotherapy for carcinoma of the cervical esophagus.
  • The methods and results of treatment for cancer of the cervical esophagus differ from those for cancer of the thoracic esophagus.
  • Our objective was to retrospectively review the outcome for cervical esophageal cancer patients treated with radiotherapy.
  • Twenty-seven patients with carcinoma of the cervical esophagus treated with definitive radiotherapy from 1988 to 2002 were enrolled in the study.
  • The mean radiation dose was 66 Gy.
  • Concurrent chemotherapy (cisplatin and 5-fluorouracil) was performed in 23 patients.
  • With univariate analysis, only two of the possible prognostic factors were found to actually influence survival: performance status (p < 0.01) and tumor length (p < 0.01).
  • The survival of patients with cervical esophageal cancer remains poor.
  • It is thought that organ preservation is possible by definitive chemoradiation for early cancer.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17118849.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


7. Ruhstaller T, Templeton A, Ribi K, Schuller JC, Borner M, Thierstein S, von Moos R, Pederiva S, Lohri A, Lombriser N, von Briel C, Koeberle D, Popescu R: Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). Onkologie; 2010;33(5):222-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02).
  • BACKGROUND: There is no standard treatment for patients with locally advanced esophageal carcinoma without systemic metastasis in whom surgery is no longer considered a reasonable option.
  • PATIENTS AND METHODS: Patients with cervical esophageal tumors, locally very advanced stage (T4 and/or M1a) or locally advanced (T3 and/or N+) with comorbidities were included.
  • THERAPY: 2 cycles of induction chemotherapy (cisplatin and docetaxel, both 75 mg/m(2) 3-weekly) followed by chemoradiation therapy (CRT) comprising a total radiation dose of 59.4 Gy together with docetaxel 15 mg/m(2) and cisplatin 25 mg/m(2) (5 weekly doses).
  • RESULTS: 21 patients were included: 12 had locally very advanced tumors, 3 had cervical esophagus tumors, and 6 were medically unfit for surgery.
  • 18 patients completed therapy per protocol.
  • Most patients experienced lasting improvement of dysphagia following induction chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Radiotherapy, Conformal
  • [MeSH-minor] Aged. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Feasibility Studies. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • [CommentIn] Onkologie. 2010;33(5):220-1 [20502055.001]
  • (PMID = 20502056.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


8. Chiewvit P, Danchaivijitr N, Sirivitmaitrie K, Chiewvit S, Thephamongkhol K: Does magnetic resonance imaging give value-added than bone scintigraphy in the detection of vertebral metastasis? J Med Assoc Thai; 2009 Jun;92(6):818-29
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does magnetic resonance imaging give value-added than bone scintigraphy in the detection of vertebral metastasis?
  • The MR imaging findings were studied: location (cervical or thoracic or lumbar or sacrum spine), number of lesions (solitary or multiple lesions), pattern of enhancement (homogeneous or inhomogeneous), involvement of spinal canal, compression of spinal cord, extradural extension, other incidental findings such as pulmonary metastasis, pleural effusion, lymphadenopathy The final diagnosis was confirmed clinically and followed-up for further management (radiation or surgery) or followed-up by MR imaging (1 month-16 months) and bone scintigraphy (5 months-12 months).
  • Primary neoplasms include breast cancer (n=11), colorectal cancer (n=7), lung cancer (n=6), prostate cancer (n=5), nasopharyngeal cancer (n=5), head and neck cancer (n=3), thyroid cancer (n=2), liver cancer (n=2), esophagus cancer (n=1), bladder cancer (n=1), retroperitoneum cancer (n=1), medulloblastoma (n=1), cervical cancer (n=1), ovarian cancer (n=1), malignant melanoma (n=1).
  • Furthermore, MR imaging is important for the further treatment planning such as radiation therapy or systemic chemotherapy.
  • Although MR imaging is useful in the detection of early metastasis that are localized completely in the bone marrow cavity routinely bone scintigraphy remains that most cost-effective method for examination of the entire skeleton.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Diphosphonates. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / radionuclide imaging. Organotechnetium Compounds. Radionuclide Imaging. Retrospective Studies. Spinal Cord Compression. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530588.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Organotechnetium Compounds; 0 / technetium 99m methylene bisphosphonate
  •  go-up   go-down


9. Nguyen NP, Smith HJ, Moltz CC, Frank C, Millar C, Dutta S, Lee H, North D, Karlsson U, Vos P, Nguyen LM, Sallah S: Prevalence of pharyngeal and esophageal stenosis following radiation for head and neck cancer. J Otolaryngol Head Neck Surg; 2008 Apr;37(2):219-24
Hazardous Substances Data Bank. Barium sulfate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: Patients who complained of persistent dysphagia following radiation alone or combined with surgery or chemotherapy for head and neck cancer.
  • Patients were selected if they were cancer free at the time of the swallowing study.
  • Traditional barium swallow confirmed the diagnosis of pharyngeal (n = 2) or esophageal (n = 14) stenosis in 16 patients.
  • CONCLUSION: Pharyngeal and/or cervical esophageal stenosis may be the cause of dysphagia following radiation for head and neck cancer.
  • [MeSH-major] Esophageal Stenosis / epidemiology. Esophagus / radiation effects. Otorhinolaryngologic Neoplasms / radiotherapy. Pharyngeal Diseases / epidemiology. Pharynx / radiation effects. Radiation Injuries / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Barium Sulfate. Combined Modality Therapy. Constriction, Pathologic / epidemiology. Constriction, Pathologic / radiography. Constriction, Pathologic / therapy. Contrast Media. Cross-Sectional Studies. Deglutition Disorders / epidemiology. Deglutition Disorders / radiography. Dilatation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. United States

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Throat Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19128616.001).
  • [ISSN] 1916-0216
  • [Journal-full-title] Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
  • [ISO-abbreviation] J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Contrast Media; 25BB7EKE2E / Barium Sulfate
  •  go-up   go-down


10. Yano M, Takachi K, Doki Y, Miyashiro I, Kishi K, Noura S, Eguchi H, Yamada T, Ohue M, Ohigashi H, Sasaki Y, Ishikawa O, Matsunaga T, Imaoka S: Prognosis of patients who develop cervical lymph node recurrence following curative resection for thoracic esophageal cancer. Dis Esophagus; 2006;19(2):73-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of patients who develop cervical lymph node recurrence following curative resection for thoracic esophageal cancer.
  • Patients with esophageal cancer often display relapse at cervical nodes after surgery, but their prognosis and a suitable therapy remains unknown.
  • We retrospectively reviewed the records for 35 patients who underwent esophagectomy with lymphadenectomy who then displayed relapse at the cervical lymph nodes alone between 1985 and 2003 in order to observe the prognostic factors for such patients.
  • Median survival time from the date of recurrence for all 35 patients was 12 months with 1-year, 2-year, 3-year and 5-year survival rate of 47.2%, 26.5%, 17.7% and 8.8%, respectively.
  • With regard to the initial treatment against cervical node recurrence, 15 patients were treated by radiotherapy alone, eight by chemoradiotherapy, 11 by surgery and one by chemotherapy alone.
  • Univariate analysis revealed that cervical node dissection at the prior esophagectomy (yes/no, P = 0.0178), time to recurrence (> 9 months or < 9 months, P = 0.0497) and the number of relapsed nodes (solitary/multiple, P = 0.0029) were significant prognostic factors.
  • In conclusion, cervical node metastasis is generally considered to be distant organ metastasis.
  • However, if it is a solitary node recurrence, substantial survival can be attained by appropriate loco-regional therapy.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643173.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Osugi H, Takemura M, Morimura K, Kaneko M, Higashino M, Takada N, Lee S, Kinoshita H: Clinicopathologic and immunohistochemical features of surgically resected small cell carcinoma of the esophagus. Oncol Rep; 2002 Nov-Dec;9(6):1245-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and immunohistochemical features of surgically resected small cell carcinoma of the esophagus.
  • Esophageal small cell carcinoma (SmC) is considered an aggressive cancer carrying a poor prognosis, although the rarity of this tumor has impeded statistical evaluation.
  • We reviewed records of 457 esophageal cancer patients treated in our department from 1986 to 2000, comparing clinicopathologic factors and post-treatment outcomes, for 9 patients with SmC, most undergoing esophagectomy including lymphadenectomy, with data from 128 patients with esophageal squamous cell carcinoma (SqC) invading to the muscular layer or beyond.
  • All SmC patients had lymph node metastasis (thoracic nodes, 9 patients: abdominal 6; cervical 1).
  • While SmC shows aggressive behavior and worse outcomes than SqC, combining esophagectomy with chemotherapy or radiotherapy may prolong survival.
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Case-Control Studies. Esophagus / pathology. Female. Humans. Immunoenzyme Techniques. Incidence. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Postoperative Complications. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12375028.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. Li AF, Hsu HS, Hsu CY, Li AC, Li WY, Liang WY, Chen JY: A 20-year retrospective study of small-cell carcinomas in Taiwan. J Surg Oncol; 2010 Oct 1;102(5):497-502
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study aimed to examine the distribution, treatment, and survival of SCCs.
  • RESULTS: The lung (89.2%) was the most common location, followed by the esophagus (1.8%), urinary bladder (1.6%), uterine cervix (1.5%), colorectum (1.4%), skin (1.0%), stomach (0.9%), head and neck (0.7%), prostate (0.3%), and small intestine (0.1%).
  • Limited disease (LD) SCLC patients underwent surgery and chemotherapy had significantly higher survival rates than those who received chemotherapy alone, those who underwent combined radiotherapy and chemotherapy, and those who were administered supportive treatment.
  • The survival rates for lung and stomach SCC patients with LD were significantly better than for patients with ED; cervical SCC stages I and IIa patients had better survival rates than patients with stage IIb and above (P = 0.034).
  • The need for combined surgery and chemotherapy in LD-SCLC patients deserves further evaluation.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Gastrointestinal Neoplasms / mortality. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / therapy. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Taiwan. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] J. Surg. Oncol. 2010;102:497-502. © 2010 Wiley-Liss, Inc.
  • (PMID = 20872953.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Wong SK, Chiu PW, Leung SF, Cheung KY, Chan AC, Au-Yeung AC, Griffith JF, Chung SS, Ng EK: Concurrent chemoradiotherapy or endoscopic stenting for advanced squamous cell carcinoma of esophagus: a case-control study. Ann Surg Oncol; 2008 Feb;15(2):576-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy or endoscopic stenting for advanced squamous cell carcinoma of esophagus: a case-control study.
  • The CRT consists of continuous infusion of 5-fluorouracil at 200 mg/m(2)/day, and cisplatin at 60 mg/m(2) on days 1 and 22, with concurrent radiotherapy for a total of 50 to 60 Gy in 25 to 30 fractions over 6 weeks.
  • Efficacy was assessed by endoscopy and computed tomographic scan before and 8 weeks after completion of the treatment program.
  • RESULTS: From 1996 to 2003, a total of 36 consecutive patients (33 male, mean +/- SD age 63.2 +/- 9.5 years) with T4 disease (81%) with or without cervical nodal metastasis (50%) received CRT, while 36 patients treated with endoscopic stenting alone were recruited as controls.
  • Both groups were comparable in demographics, pretreatment dysphagia score, comorbidities, and tumor characteristics.
  • There was no treatment-related mortality.
  • Tumor volume was greatly reduced after CRT in 19 patients.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Esophagoscopy. Fluorouracil / administration & dosage. Stents
  • [MeSH-minor] Aged. Case-Control Studies. Combined Modality Therapy. Comorbidity. Deglutition Disorders / drug therapy. Deglutition Disorders / radiotherapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057993.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB Jr, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R: Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys; 2004 Dec 1;60(5):1484-93
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the effect of surgical resection on the outcome of patients with clinical Stage II or III cancer of the esophagus treated with concurrent chemoradiotherapy.
  • The median radiation dose was 50 Gy (range, 30-64.8 Gy) in the definitive chemoradiation group and 45 Gy (range, 30-50.4 Gy) in the chemoradiation plus esophagectomy group.
  • RESULTS: Statistically significant differences were found between the two groups in median age, histologic subtype, tumor location, and number of patients with T4 disease.
  • Patients who underwent definitive chemoradiotherapy were older (p = 0.0004) and more likely to have squamous cell carcinoma than adenocarcinoma (p <0.000), upper thoracic or cervical esophageal tumors (p <0.000), and T4 tumors (p = 0.024).
  • Patients treated with chemoradiation plus esophagectomy had statistically significant superior 5-year loco-regional control (67.1% vs. 22.1%, p <0.000), disease-free survival (40.7% vs. 9.9%, p < 0.000), and 5-year overall survival (52.6% vs. 6.5%, p < 0.000) rates and median survival time (62 vs. 12 months) compared with patients treated with chemoradiotherapy only.
  • Surgical resection of the tumor was an independent predictor of improved locoregional control and overall survival in both univariate and multivariate analyses.
  • The results from this study suggest the need for a randomized trial to compare chemoradiation with or without esophagectomy in the treatment of cancer of the esophagus.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Treatment Failure

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15590179.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Swanson SJ, Batirel HF, Bueno R, Jaklitsch MT, Lukanich JM, Allred E, Mentzer SJ, Sugarbaker DJ: Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg; 2001 Dec;72(6):1918-24; discussion 1924-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma.
  • This study examines the morbidity, mortality, and early survival of patients after transthoracic esophagectomy for esophageal carcinoma using current staging techniques and neoadjuvant therapy.
  • The technique includes right thoracotomy, laparotomy, and cervical esophagogastrostomy (total thoracic esophagectomy) with radical mediastinal and abdominal lymph node dissection.
  • Eighty-one percent (202) had induction chemotherapy (all patients with clinical T3/4 or N1).
  • Five patients with tumor in situ, 6 patients with stage IV disease, and 1 patient who could not be staged (12 pts) were excluded from survival and multivariate calculations.
  • CONCLUSIONS: Total thoracic esophagectomy with node dissection for esophageal cancer appears to have acceptable morbidity and mortality with encouraging survival results in the setting of neoadjuvant therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Gastrostomy / methods. Lymph Node Excision / methods. Precancerous Conditions / surgery
  • [MeSH-minor] Abdomen / surgery. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Mediastinum / surgery. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11789772.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


16. Bizekis C, Kent MS, Luketich JD, Buenaventura PO, Landreneau RJ, Schuchert MJ, Alvelo-Rivera M: Initial experience with minimally invasive Ivor Lewis esophagectomy. Ann Thorac Surg; 2006 Aug;82(2):402-6; discussion 406-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our standard approach involves laparoscopic and thoracoscopic mobilization of the esophagus with a cervical esophagogastric anastomosis.
  • The planned approach included a totally laparoscopic abdominal procedure and either a minithoracotomy or thoracoscopy.
  • Indications for esophagectomy included short segment Barrett's esophagus with high-grade dysplasia or resectable adenocarcinoma of the gastroesophageal junction (GEJ) with minimal proximal esophageal extension. .
  • Twenty-five patients (50%) received either preoperative chemotherapy or chemoradiation.
  • There was one nonemergent conversion to an open procedure during laparoscopy.
  • Three patients (6%) developed an anastomotic leak; all were successfully managed nonoperatively.
  • Four patients (8%) developed postoperative pneumonia.
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures. Neoplasm Staging. Postoperative Complications / etiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16863737.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


17. Brändlein S, Pohle T, Vollmers C, Wozniak E, Ruoff N, Müller-Hermelink HK, Vollmers HP: CFR-1 receptor as target for tumor-specific apoptosis induced by the natural human monoclonal antibody PAM-1. Oncol Rep; 2004 Apr;11(4):777-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CFR-1 receptor as target for tumor-specific apoptosis induced by the natural human monoclonal antibody PAM-1.
  • This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia.
  • Both, the unique tumor-specific expression of the CFR-1/PAM-1 receptor and the growth inhibitory effect of the PAM-1 antibody makes this combination a good diagnostic and therapeutic tool for all kinds of epithelial cancers and precursor lesions.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Apoptosis. Carcinoma / drug therapy. Receptors, Cell Surface / antagonists & inhibitors. Sialoglycoproteins / antagonists & inhibitors
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Animals. Biological Assay. Cell Line, Tumor. Humans. Immunochemistry. Mice. Mice, Inbred Strains. Neoplasm Transplantation. Pepsin A / chemistry. Receptors, Fibroblast Growth Factor. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Oncol Rep. 2004 Jul;12(1):201
  • (PMID = 15010872.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / PAM-1 monoclonal antibody, human; 0 / Receptors, Cell Surface; 0 / Receptors, Fibroblast Growth Factor; 0 / Sialoglycoproteins; 0 / cysteine-rich fibroblast growth factor receptor; EC 3.4.23.1 / Pepsin A
  •  go-up   go-down


18. Fink W, Zimpfer A, Ugurel S: Mucosal metastases in malignant melanoma. Onkologie; 2003 Jun;26(3):249-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We present the case of a patient with malignant melanoma stage IV according to the American Joint Committee on Cancer (AJCC) classification and an unusual pattern of metastasis to the mucosa of the esophagus, the stomach, the bladder and the palatine tonsil.
  • CASE REPORT: A 38-year-old male patient with metastatic malignant melanoma of stage III (AJCC) was admitted for initiation of adjuvant therapy.
  • On admission the patient complained of a sore throat and right cervical lymphadenopathy.
  • Two cycles of dacarbazine (DTIC) chemotherapy were performed during which the patient developed cutaneous metastases, dyspepsia, and mild hematemesis.
  • Gastroscopy revealed bleeding from mucosal metastases of the esophagus and stomach.
  • A few weeks later the patient developed macroscopic hematuria.
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Gastric Mucosa / pathology. Humans. Male. Mucous Membrane / pathology. Neoplasm Staging. Tomography, Emission-Computed


19. Schilling MK, Plinkert P: [Interdisciplinary surgery-the throat]. Chirurg; 2004 Apr;75(4):347-53
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The special anatomic situation and the multitude of combinations of oncological therapeutic and reconstructive modalities in tumors of the cervical region require intensive interdisciplinary planning and discussion during tumor staging, surgical resection, and (neo)adjuvant treatment.
  • We discuss here the various treatment modalities for tumors of the pharynx and cervical esophagus.
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Microsurgery. Neoplasm Staging. Radiotherapy, Adjuvant. Speech, Alaryngeal. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Feb;121(2):162-5 [7840923.001]
  • [Cites] Laryngoscope. 2001 May;111(5):807-10 [11359159.001]
  • [Cites] Plast Reconstr Surg. 1982 Sep;70(3):336-44 [6125980.001]
  • [Cites] World J Surg. 2002 May;26(5):561-5 [12098046.001]
  • [Cites] Arch Otolaryngol. 1976 Dec;102(12):716-21 [803064.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Jan;124(1):58-67 [11228455.001]
  • [Cites] Laryngorhinootologie. 1993 Nov;72(11):537-44 [8305118.001]
  • [Cites] Am J Surg. 1980 Oct;140(4):507-13 [7425233.001]
  • [Cites] Br J Plast Surg. 1981 Jan;34(1):3-10 [7459521.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1998 Jul;107(7):581-7 [9682853.001]
  • [Cites] HNO. 2002 Dec;50(12 ):1068-74 [12474129.001]
  • [Cites] Laryngoscope. 2001 Jul;111(7):1192-6 [11568540.001]
  • [Cites] HNO. 1993 Apr;41(4):206-14 [8514527.001]
  • [Cites] Plast Reconstr Surg. 1965 Aug;36:173-84 [14339173.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 May;124(5):561-9 [11337663.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1997 Feb;22(1):41-3 [9088678.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] World J Surg. 1997 Nov-Dec;21(9):992-7 [9361516.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Ann Chir. 2002 Jun;127(6):431-8 [12122716.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Sep;124(9):951-62 [9738803.001]
  • [Cites] Laryngorhinootologie. 2003 May;82 Suppl 1:S114-43 [12717612.001]
  • [Cites] Br J Surg. 1960 Sep;48:193-200 [13730974.001]
  • [Cites] Laryngoscope. 1997 Aug;107(8):1005-17 [9260999.001]
  • [Cites] Acta Chir Plast. 2002;44(4):120-3 [12661925.001]
  • [Cites] HNO. 1993 May;41(5):268-73 [8335488.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 Mar;15(3):327-31; discussion 331-2 [10333031.001]
  • (PMID = 15045205.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Khoury-Helou A, Lozac'h C, Vandenbrouke F, Lozac'h P: [Primary malignant melanoma of the esophagus]. Ann Chir; 2001 Jul;126(6):557-60
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant melanoma of the esophagus].
  • [Transliterated title] Le mélanome malin primitif de l'oesophage.
  • The primary malignant melanoma of the esophagus is a rare tumor.
  • The study aim was to report two cases, one treated by esophagectomy without thoracotomy and the other one by Lewis-Santy type esophagectomy.
  • The other one who had a cervical invaded lymph node, treated by radio-chemotherapy, is actually in complete remission 9 years after the diagnosis.
  • [MeSH-minor] Aged. Combined Modality Therapy. Fatal Outcome. Humans. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local. Thoracotomy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11486540.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down






Advertisement